These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 31767465

  • 1. Immunogenicity and safety of vaccination against seasonal influenza vaccine in patients with psoriatic arthritis treated with secukinumab.
    Furer V, Zisman D, Kaufman I, Arad U, Berman M, Sarbagil-Maman H, Elias M, Hadad A, Paran D, Drori Y, Friedman N, Mandelboim M, Elkayam O.
    Vaccine; 2020 Jan 22; 38(4):847-851. PubMed ID: 31767465
    [Abstract] [Full Text] [Related]

  • 2. Immunogenicity and safety of vaccination against seasonal 2012 influenza virus among patients with psoriatic arthritis and psoriasis.
    Polachek A, Korobko U, Mader-Balakirski N, Arad U, Levartovsky D, Kaufman I, Anouk M, Litinsky I, Wigler I, Mendelson E, Paran D, Matz H, Caspi D, Mandelboim M, Elkayam O.
    Clin Exp Rheumatol; 2015 Jan 22; 33(2):181-6. PubMed ID: 25738420
    [Abstract] [Full Text] [Related]

  • 3. Vaccination against influenza in patients with systemic sclerosis.
    Litinsky I, Balbir A, Zisman D, Mandelboim M, Mendelson E, Feld J, Braun Y, Anouk M, Kaufman I, Paran D, Caspi D, Elkayam O.
    Clin Exp Rheumatol; 2012 Jan 22; 30(2 Suppl 71):S7-11. PubMed ID: 22409886
    [Abstract] [Full Text] [Related]

  • 4. Secukinumab does not impair the immunogenic response to the influenza vaccine in patients.
    Richi P, Martín MD, de Ory F, Gutiérrez-Larraya R, Casas I, Jiménez-Díaz AM, Cava F, Muñoz-Fernandez S.
    RMD Open; 2019 Jan 22; 5(2):e001018. PubMed ID: 31565246
    [Abstract] [Full Text] [Related]

  • 5. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB, Neuzil KM, Zhu Y, Fairchok MP, Gagliano ME, Monto AS, Englund JA.
    Pediatrics; 2006 Sep 22; 118(3):e570-8. PubMed ID: 16950948
    [Abstract] [Full Text] [Related]

  • 6. A prospective, double-blind, randomized, placebo-controlled study on the efficacy and safety of influenza vaccination in myasthenia gravis.
    Strijbos E, Tannemaat MR, Alleman I, de Meel RHP, Bakker JA, van Beek R, Kroon FP, Rimmelzwaan GF, Verschuuren JJGM.
    Vaccine; 2019 Feb 08; 37(7):919-925. PubMed ID: 30660402
    [Abstract] [Full Text] [Related]

  • 7. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
    Englund JA, Walter EB, Gbadebo A, Monto AS, Zhu Y, Neuzil KM.
    Pediatrics; 2006 Sep 08; 118(3):e579-85. PubMed ID: 16950949
    [Abstract] [Full Text] [Related]

  • 8. Immunogenicity of a 2009 pandemic influenza virus A H1N1 vaccine, administered simultaneously with the seasonal influenza vaccine, in children receiving chemotherapy.
    Ottóffy G, Horváth P, Muth L, Sólyom A, Garami M, Kovács G, Nyári T, Molnár D, Pauler G, Jankovics I.
    Pediatr Blood Cancer; 2014 Jun 08; 61(6):1013-6. PubMed ID: 24395342
    [Abstract] [Full Text] [Related]

  • 9. Quadrivalent Influenza Vaccine-Induced Antibody Response and Influencing Determinants in Patients ≥ 55 Years of Age in the 2018/2019 Season.
    Ganczak M, Dubiel P, Drozd-Dąbrowska M, Hallmann-Szelińska E, Szymański K, Brydak LB.
    Int J Environ Res Public Health; 2019 Nov 14; 16(22):. PubMed ID: 31739554
    [Abstract] [Full Text] [Related]

  • 10. Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18-64 years of age.
    Gorse GJ, Falsey AR, Fling JA, Poling TL, Strout CB, Tsang PH.
    Vaccine; 2013 May 01; 31(19):2358-65. PubMed ID: 23499604
    [Abstract] [Full Text] [Related]

  • 11. Safety and immunogenicity of the novel seasonal preservative- and adjuvant-free influenza vaccine: Blind, randomized, and placebo-controlled trial.
    Sarsenbayeva G, Volgin Y, Kassenov M, Issagulov T, Bogdanov N, Sansyzbay A, Abitay R, Nurpeisova A, Sagymbay A, Koshemetov Z, Stukova M, Buzitskaya Z, Кulmagambetov I, Karabayeva D, Davlyatshin T, Khairullin B.
    J Med Virol; 2018 Jan 01; 90(1):41-49. PubMed ID: 28842994
    [Abstract] [Full Text] [Related]

  • 12. Immunogenicity and safety of a novel seasonal influenza preservative-free vaccine manufactured in Kazakhstan: Results of a randomized, comparative, phase II clinical trial in adults.
    Sarsenbayeva G, Volgin Y, Kassenov M, Issagulov T, Bogdanov N, Sansyzbay A, Stukova M, Buzitskaya Z, Кulmagambetov I, Davlyatshin T, Khairullin B.
    Hum Vaccin Immunother; 2018 Mar 04; 14(3):609-614. PubMed ID: 29112488
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of vaccination against pandemic 2009 influenza A (H1N1) virus among patients with rheumatic diseases.
    Elkayam O, Amir S, Mendelson E, Schwaber M, Grotto I, Wollman J, Arad U, Brill A, Paran D, Levartovsky D, Wigler I, Caspi D, Mandelboim M.
    Arthritis Care Res (Hoboken); 2011 Jul 04; 63(7):1062-7. PubMed ID: 21425247
    [Abstract] [Full Text] [Related]

  • 14. Immunogenicity of aIIV3, MF59-adjuvanted seasonal trivalent influenza vaccine, in older adults ≥65 years of age: Meta-analysis of cumulative clinical experience.
    Nicolay U, Heijnen E, Nacci P, Patriarca PA, Leav B.
    Int J Infect Dis; 2019 Aug 04; 85S():S1-S9. PubMed ID: 30926542
    [Abstract] [Full Text] [Related]

  • 15. Influenza Vaccine-Induced Antibody Responses Are Not Impaired by Frailty in the Community-Dwelling Elderly With Natural Influenza Exposure.
    Narang V, Lu Y, Tan C, Camous XFN, Nyunt SZ, Carre C, Mok EWH, Wong G, Maurer-Stroh S, Abel B, Burdin N, Poidinger M, Tambyah PA, Bosco N, Visan L, Ng TP, Larbi A.
    Front Immunol; 2018 Aug 04; 9():2465. PubMed ID: 30405641
    [Abstract] [Full Text] [Related]

  • 16. Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response.
    Oren S, Mandelboim M, Braun-Moscovici Y, Paran D, Ablin J, Litinsky I, Comaneshter D, Levartovsky D, Mendelson E, Azar R, Wigler I, Balbir-Gurman A, Caspi D, Elkayam O.
    Ann Rheum Dis; 2008 Jul 04; 67(7):937-41. PubMed ID: 17981914
    [Abstract] [Full Text] [Related]

  • 17. Immune responses to intradermal and intramuscular inactivated influenza vaccine among older age group.
    Boonnak K, Dhitavat J, Thantamnu N, Kosoltanapiwat N, Auayporn M, Jiang L, Puthavathana P, Pitisuttithum P.
    Vaccine; 2017 Dec 19; 35(52):7339-7346. PubMed ID: 29157960
    [Abstract] [Full Text] [Related]

  • 18. Influenza A/Singapore (H3N2) component vaccine in systemic lupus erythematosus: A distinct pattern of immunogenicity.
    Claudino Formiga FF, Silva CA, Pedrosa TDN, Aikawa NE, Pasoto SG, Garcia CC, Capão ASV, Martins VAO, Proença ACT, Fuller R, Yuki EFN, Vendramini MBG, Rosário DCD, Brandão LMKR, Sartori AMC, Antonangelo L, Bonfá E, Borba EF.
    Lupus; 2021 Oct 19; 30(12):1915-1922. PubMed ID: 34459317
    [Abstract] [Full Text] [Related]

  • 19. Immunogenicity and safety of MF59-adjuvanted quadrivalent influenza vaccine versus standard and alternate B strain MF59-adjuvanted trivalent influenza vaccines in older adults.
    Essink B, Fierro C, Rosen J, Figueroa AL, Zhang B, Verhoeven C, Edelman J, Smolenov I.
    Vaccine; 2020 Jan 10; 38(2):242-250. PubMed ID: 31635976
    [Abstract] [Full Text] [Related]

  • 20. The priming effect of previous natural pandemic H1N1 infection on the immunogenicity to subsequent 2010-2011 influenza vaccination in children: a prospective cohort study.
    Kang EK, Eun BW, Kim NH, Lim JS, Lee JA, Kim DH.
    BMC Infect Dis; 2016 Aug 22; 16(1):438. PubMed ID: 27549626
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.